These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 20459883)

  • 1. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
    Fleischhacker WW; Heikkinen ME; Olié JP; Landsberg W; Dewaele P; McQuade RD; Loze JY; Hennicken D; Kerselaers W
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1115-25. PubMed ID: 20459883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
    Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
    Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
    Chang JS; Ahn YM; Park HJ; Lee KY; Kim SH; Kang UG; Kim YS
    J Clin Psychiatry; 2008 May; 69(5):720-31. PubMed ID: 18370574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
    Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
    J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
    Henderson DC; Kunkel L; Nguyen DD; Borba CP; Daley TB; Louie PM; Freudenreich O; Cather C; Evins AE; Goff DC
    Acta Psychiatr Scand; 2006 Feb; 113(2):142-7. PubMed ID: 16423166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
    Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
    Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Scimeca G; Di Nardo F; Santoro V; Spina E; Zoccali RA
    Schizophr Res; 2011 Apr; 127(1-3):93-9. PubMed ID: 21262565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
    Sachs G; Sanchez R; Marcus R; Stock E; McQuade R; Carson W; Abou-Gharbia N; Impellizzeri C; Kaplita S; Rollin L; Iwamoto T;
    J Psychopharmacol; 2006 Jul; 20(4):536-46. PubMed ID: 16401666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
    De Risio A; Pancheri A; Simonetti G; Giannarelli D; Stefanutto L; Gentile B
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1112-6. PubMed ID: 21447367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.